NGL Fine Chem Reports Q1 Net Profit Of ₹18.4 Crore, Up 100% YoY

Market snapshot: NGL Fine Chem Limited reported strong financial results for the first quarter of FY27, with consolidated net profit doubling YoY to ₹18.4 crore. Revenue from operations grew 34.62% YoY to ₹140 crore, supported by a 111.82% YoY surge in EBITDA to ₹23.3 crore. EBITDA margins expanded significantly by 620 basis points to 16.74%, highlighting robust operating leverage.

Data Snapshot

• Consolidated net profit reached ₹18.4 crore, marking a 100% increase compared to ₹9.2 crore in the prior-year period.
• Consolidated revenue from operations grew to ₹140 crore, representing a growth of 34.62% YoY compared to ₹104 crore.
• Consolidated EBITDA stood at ₹23.3 crore, up 111.82% YoY from ₹11 crore in Q1 FY26.
• Operating margin improved to 16.74%, expanding by 620 basis points YoY compared to 10.54% in Q1 FY26.

What's Changed

• Revenue dropped sequentially by 6.08% compared to ₹149.07 crore in Q4 FY26.
• Consolidated net profit rose sequentially by 35.59% compared to ₹13.57 crore in Q4 FY26.
• EBITDA margins expanded sequentially from 11.81% in Q4 FY26 (derived: EBITDA of ₹17.6 crore on revenue of ₹149.07 crore) to 16.74% in Q1 FY27.

Key Takeaways

• Operating leverage kicked in significantly as EBITDA and net profit grew at more than double the rate of revenue expansion YoY.
• Sequential margins improved substantially despite a minor decline in quarterly revenue, showing strong cost optimization.
• Long-term structural growth is supported by substantial capacity additions, with capital work-in-progress rising to ₹94.56 crore in FY26.
• Shareholders will be rewarded with an upcoming final dividend of ₹1.75 per equity share, carrying an ex-date of August 18, 2026.

SAHI Perspective

NGL Fine Chem's Q1 FY27 performance demonstrates strong operating leverage, where EBITDA and net profit grew significantly faster than revenue. The sequential expansion in profitability, despite a small drop in quarterly revenue, points to successful cost controls and potential stabilization of raw material costs in the API segment. As new capacities come online, NGL's volume-driven growth strategy should continue to support high-teens EBITDA margins.

Market Implications

The strong earnings performance is highly positive for investor sentiment, likely reinforcing the stock's recent upward momentum. The market-beating margins and profit growth justify the premium valuations the stock currently commands. Furthermore, the upcoming ex-dividend date on August 18, 2026, could provide short-term support to the share price.

Trading Signals

Market Bias: Bullish

Stellar YoY financial results with net profit doubling and operating margins expanding by 620 bps to 16.74%. Strong execution and operational leverage support a bullish medium-term bias.

Overweight: Pharmaceuticals, APIs & Intermediates

Trigger Factors:

• Ex-dividend date of ₹1.75 per share on August 18, 2026
• Successful commissioning and ramp-up of capacity expansions
• Sustained quarterly margins above 15%

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian API and pharmaceutical manufacturing sector is experiencing structural tailwinds as global drugmakers seek alternative supply sources. While the sector has faced headwinds like raw material price volatility and high competition, players like NGL Fine Chem are mitigating these through capacity expansion and maintaining price stability for long-term customer retention.

Key Risks to Watch

• Volatile raw material costs impacting operating margins.
• Delays in executing and commercializing the ongoing capital work-in-progress programs.
• Regulatory changes or audits affecting manufacturing facilities.

Recent Developments

In late May 2026, NGL Fine-Chem reported strong FY26 results with consolidated revenue growing 36% to ₹500.95 crore and net profit surging 128% to ₹48.12 crore. The company proposed a final dividend of ₹1.75 per share with the ex-dividend date set for August 18, 2026. Prior to this, in March 2026, Crisil Ratings upgraded the company's long-term credit rating outlook to 'Stable'.

Closing Insight

NGL Fine Chem's Q1 FY27 results reinforce its position as a high-growth, financially disciplined pharmaceutical player. By doubling its bottom line and showing sequential margin improvements, the company proves that its operational execution can deliver high returns even during sequential volume fluctuations.

High Performance Trading with SAHI.